Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations Journal Article

   

Authors:	Buczkowicz, P.; Hoeman, C.; Rakopoulos, P.; Pajovic, S.; Letourneau, L.; Dzamba, M.; Morrison, A.; Lewis, P.; Bouffet, E.; Bartels, U.; Zuccaro, J.; Agnihotri, S.; Ryall, S.; Barszczyk, M.; Chornenkyy, Y.; Bourgey, M.; Bourque, G.; Montpetit, A.; Cordero, F.; Castelo-Branco, P.; Mangerel, J.; Tabori, U.; Ho, K. C.; Huang, A.; Taylor, K. R.; Mackay, A.; Bendel, A. E.; Nazarian, J.; Fangusaro, J. R.; Karajannis, M. A.; Zagzag, D.; Foreman, N. K.; Donson, A.; Hegert, J. V.; Smith, A.; Chan, J.; Lafay-Cousin, L.; Dunn, S.; Hukin, J.; Dunham, C.; Scheinemann, K.; Michaud, J.; Zelcer, S.; Ramsay, D.; Cain, J.; Brennan, C.; Souweidane, M. M.; Jones, C.; Allis, C. D.; Brudno, M.; Becher, O.; Hawkins, C.
Article Title:	Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations
Abstract:	Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer. © 2014 Nature America, Inc. All rights reserved.
Journal Title:	Nature Genetics
Volume:	46
Issue:	5
ISSN:	1061-4036
Publisher:	Nature Publishing Group
Date Published:	2014-05-01
Start Page:	451
End Page:	456
Language:	English
DOI:	10.1038/ng.2936
PROVIDER:	scopus
PMCID:	PMC3997489
PUBMED:	24705254
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84899570180&partnerID=40&md5=1c6a412790df5aeec3b633ac2aad9277
Notes:	Nat. Genet. -- Cited By (since 1996):1 -- Export Date: 2 June 2014 -- CODEN: NGENE -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/51716